An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas.

BMC Cancer · 2011 · PMC3149030 · PMID 21756326

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Combined mEGFR/CRM1 showed a trend for unfavorable overall survival in all carcinomas (HR 3.3, CI 0.9-11.7, p = 0.06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.